BOSTON, Sept. 19, 2019 /PRNewswire/ -- The future of health is expected to be driven by an omnipresent, proactive, and integrated system aimed at health and well-being, where transformational technologies (e.g., artificial intelligence, digital therapeutics, cloud and app-enabled digital health capabilities, augmented and virtual reality) are poised to play a significant role. New research for the medical-technology ("medtech") industry from Deloitte finds that these emerging technologies can result in a dramatic change to traditional medtech business models, opening up an opportunity for enhanced collaboration with consumer technology and digital health companies to transform the delivery of care.
The Deloitte Center for Health Solutions recently conducted a crowdsourcing simulation with experts across digital health start-ups, medtech companies, technology companies, health plans, health systems, and research institutions to better understand what the medtech company of the future might look like.
Partnering for the future
The research revealed one particularly important finding: medtech companies that have traditionally focused on developing hardware (e.g., surgical equipment, joint replacements, diagnostic equipment, infusion pumps, pacemakers, etc.) are shifting their focus to software, data collection, and advanced data analysis.
"What's interesting for medtech companies to know from this research is that in many ways, the data collected from their hardware could be more valuable than the hardware itself, at least as these capabilities evolve even more radically in the future," said Pedro Arboleda, managing director, Deloitte Consulting LLP. "To stay relevant in the future of health and be in a position to embrace new care models, medtech companies should consider partnering much more closely with consumer technology companies so they can continue innovating across the complete patient journey and clinician experience."
The research found that while many medtech companies are well-positioned to drive the future of health, they likely won't be able to do it alone. Developing acquiring or partnering to access sophisticated data analytics capabilities, rather than focusing on making incremental improvements to their devices, can ensure transformative capabilities that can be better able to address changing patient and clinician needs. The top technologies cited by our research, in order, were artificial intelligence (AI) (80%), robotics (53%) and nanotechnology (47%).
The future through new services
Deloitte's research also found that medtech companies will likely make the transition to the future of health through more sophisticated, data-driven services. Medtech companies are poised to play a significant role in reducing medical costs, optimizing surgical performance, and improving patient outcomes in the near-term. The top three service areas cited were remote patient monitoring (72%), data storage and integration (67%), and improving clinical efficiency (45%).
"The pace of innovation in health care is unprecedented, so medtech companies should think about what role they want to play in the future ecosystem, whether it's a data and platform provider, a well-being and care delivery organization, a care enabler, or elements of all three. Knowing where a partner may help fill any short- or long-term gaps can only position them for greater success," said Glenn Snyder, principal and medtech leader, Deloitte Consulting LLP.
To review the research paper, "Winning in the future of medtech: Novel partnerships with consumer tech to transform the delivery of care," please visit Deloitte Insights. Visit Deloitte at The MedTech Conference in Boston Sept., 23-25, 2019 in booth number one.
Deloitte provides industry-leading audit, consulting, tax and advisory services to many of the world's most admired brands, including nearly 90% of the Fortune 500® and more than 5,000 private and middle market companies. Our people work across the industry sectors that drive and shape today's marketplace — delivering measurable and lasting results that help reinforce public trust in our capital markets, inspire clients to see challenges as opportunities to transform and thrive, and help lead the way toward a stronger economy and a healthy society. Deloitte is proud to be part of the largest global professional services network serving our clients in the markets that are most important to them. Our network of member firms in more than 150 countries and territories serves four out of five Fortune Global 500® companies. Learn how Deloitte's approximately 286,000 people make an impact that matters at www.deloitte.com.
About the Deloitte Center for Health Solutions
The source for fresh perspectives in health care: The Deloitte Center for Health Solutions (DCHS), part of Deloitte LLP's Life Sciences and Health Care practice, looks deeper at the biggest industry issues and pro-vides new thinking around complex challenges. Cutting-edge research and thought-provoking analysis give our clients the insights they need to see things differently and address the changing landscape. To learn more about the DCHS and our research, please visit www.deloitte.com/centerforhealthsolutions.
Deloitte refers to one or more of Deloitte Touche Tohmatsu Limited, a UK private company limited by guarantee ("DTTL"), its network of member firms, and their related entities. DTTL and each of its member firms are legally separate and independent entities. DTTL (also referred to as "Deloitte Global") does not provide services to clients. In the United States, Deloitte refers to one or more of the US member firms of DTTL, their related entities that operate using the "Deloitte" name in the United States and their respective affiliates. Certain services may not be available to attest clients under the rules and regulations of public accounting. Please see www.deloitte.com/about to learn more about our global network of member firms.